Literature DB >> 10827394

New insights in cardiac structural changes in patients with Fabry's disease.

A Linhart1, T Palecek, J Bultas, J J Ferguson, J Hrudová, D Karetová, J Zeman, J Ledvinová, H Poupetová, M Elleder, M Aschermann.   

Abstract

BACKGROUND: Fabry's disease is an X-linked recessive genetic deficiency of the enzyme alpha-galactosidase leading to the pathologic intracellular deposition of neutral glycosphingolipids. Although cardiac involvement is frequent, there is controversy regarding the character of the associated left ventricular (LV) changes and the severity of valvular involvement.
METHODS: Clinical evaluation (disease severity scaling, laboratory tests, and echocardiography) was performed in 13 hemizygous men (mean age 39 +/- 10 years) and 17 heterozygous women (mean age 35 +/- 19 years).
RESULTS: LV hypertrophy (LVH) was frequent in subjects older than 30 years, more often in men (61%) than in women (18%, P <.001). The degree of LVH was independently associated with age and the logarithm of alpha-galactosidase activity (r(2) = 0.70, P <.001). The predominant LV geometric patterns were concentric LVH and remodeling, both present in 11 subjects (36%). Three patients had an asymmetric septal hypertrophy mimicking hypertrophic cardiomyopathy. In most subjects with LVH, the systolic function was normal and severe diastolic dysfunction (restrictive pattern) was not noted. Minor structural abnormalities of the mitral valve were found in 17 subjects (57%). The aortic valve was affected in 14 patients (47%). Valvular abnormalities were frequently accompanied by regurgitation of minor to mild degree. The presence of LVH or valvular changes was associated with increased disease severity.
CONCLUSIONS: Echocardiographically detectable cardiac involvement is frequent with Fabry's disease, particularly in older subjects, and more pronounced in affected hemizygous men than in heterozygous women. LVH is frequently observed but usually not associated with significant systolic or restrictive diastolic dysfunction. Concentric LVH and remodeling appear to be the major manifestations of LV structural alteration. The frequently noted valvular abnormalities were not associated with a significant degree of regurgitation. Valvular and especially LV structural changes may serve as a useful marker of disease severity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10827394     DOI: 10.1067/mhj.2000.105105

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  47 in total

Review 1.  The role of echocardiographic deformation imaging in hypertrophic myopathies.

Authors:  Maja Cikes; George R Sutherland; Lisa J Anderson; Bart H Bijnens
Journal:  Nat Rev Cardiol       Date:  2010-05-11       Impact factor: 32.419

2.  Early diastolic mitral annular velocity and color M-mode flow propagation velocity in the evaluation of left ventricular diastolic function in patients with Fabry disease.

Authors:  Tomas Palecek; Ales Linhart; Jean Claude Lubanda; Sudheera Magage; Debora Karetova; Jan Bultas; Michael Aschermann
Journal:  Heart Vessels       Date:  2006-01       Impact factor: 2.037

Review 3.  The heart in Anderson-Fabry disease and other lysosomal storage disorders.

Authors:  Ales Linhart; Perry M Elliott
Journal:  Heart       Date:  2007-04       Impact factor: 5.994

Review 4.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

Authors:  Praveen G Ranganath; Albree Tower-Rader
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 5.  Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Authors:  Marianne Rohrbach; Joe T R Clarke
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Cardiac manifestations in Fabry disease.

Authors:  A Linhart; J C Lubanda; T Palecek; J Bultas; D Karetová; J Ledvinová; M Elleder; M Aschermann
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

7.  Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity.

Authors:  Justina C Wu; Carolyn Y Ho; Hicham Skali; Rekha Abichandani; William R Wilcox; Maryam Banikazemi; Seymour Packman; Katherine Sims; Scott D Solomon
Journal:  Eur Heart J       Date:  2010-01-07       Impact factor: 29.983

8.  Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease.

Authors:  Gregory Bierer; David Balfe; William R Wilcox; Zab Mosenifar
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

9.  Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.

Authors:  Kevin Mills; Ashok Vellodi; Peter Morris; Donald Cooper; Michael Morris; Elisabeth Young; Bryan Winchester
Journal:  Eur J Pediatr       Date:  2004-10       Impact factor: 3.183

10.  Early cardiovascular remodelling in Fabry disease.

Authors:  Luca Costanzo; Sergio Buccheri; Piera Capranzano; Luigi Di Pino; Giuseppina Curatolo; Margherita Rodolico; Stefano Leggio; Anita Blundo; Corrado Tamburino; Ines Monte
Journal:  J Inherit Metab Dis       Date:  2013-04-25       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.